FLEXcon launches PHARMcal portfolio

The line reduces complexity with a simplified product offering organized by end-use application, making it easier for customers and specifiers to select appropriate products for their intended use. 

The portfolio features six product families to meet the needs of specific application requirements, such as small or large diameter containers, cover-up applications, extreme storage conditions, tamper-evidence, and secondary blood bag labeling. 

All products are available globally and feature some of the company’s most high-performing adhesives, with raw material components locked down to ensure consistent quality and performance.

‘This consolidated product portfolio covers all the bases,’ said Lori Bitar, product manager, healthcare at FLEXcon. ‘Moving forward, both label converters and material specifiers can rest assured that the product they choose is appropriate for their application and that quality and performance will be consistent whether they’re producing a vaccine label, clinical trial label, plasma label, or tamper-evident box closure.’

All PHARMcal products have been tested for durability and performance. Custom testing in the company’s DAP-certified lab is available for testing against specific application requirements and competitive product analysis.